Unlock the Potential of Regulatory T Cells in Cell Therapy Manufacturing Isolating ultra-rare cell populations at high purity using the CGX10 Cell Isolation System
The isolation and expansion of rare and ultra-rare cell populations are important for advancing cell therapy manufacturing. For example, Foxp3-positive naïve regulatory T cells (nTregs) may account for <1% of cells in a sample containing 1 billion leukocytes, making it extremely challenging to isolate them with high purity.
In this webinar, we will provide data on how the CGX10 Cell Isolation System can sort these ultra-rare nTregs directly from a leukopak. We also will share data on how the CGX10 system can be utilized for isolation of positively transduced T cells expressing a green fluorescent protein (GFP) marker at <97% purity using Purity mode.
Key Learning Objectives:
- High throughput sterile isolation and expansion of Foxp3-positive nTregs from 1 billion human leukocytes from a single donor, bypassing any bead-based pre-enrichment steps
- Isolation of positively transduced T cells expressing a GFP marker at high purity
- Sorting of CD4+ and CD8+ T cells directly after an RBC lysis step, at a predefined proportion, using Custom Purity mode
Who should attend
Cell and gene therapy specialists, scientists, and engineers working in research, process development, or manufacturing for diverse applications, including CAR-Treg and Treg therapy, CAR-T, TIL-based therapy, CAR-NK therapy, immune cell therapy, and stem cell therapy.
Speaker
Tea Gogishvili, PhD
Senior Application Specialist
Sony Europe BV – Germany
Dr. Gogishvili supports customers in developing applications for spectral cell analysis and cell sorting. She received her doctoral degree in cellular immunology at the University of Würzburg, Germany, and in academic research explored the role of immune cell subsets in various disease models. As a senior scientist in the translational field of hematology (University of Würzburg), she identified new biomarkers for cell therapies and developed the CAR-T cell manufacturing processes for multiple hematological malignancies. Dr. Gogishvili has also authored publications in high impact journals.